证券代码：300723 证券简称：一品红 公告编号：2025-063 一品红药业集团股份有限公司 关于全资子公司获得左卡尼汀口服溶液注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一品红药业集团股份有限公司（以下简称"公司"）全资子公司广州一品红 制药有限公司于近日收到国家药品监督管理局核准签发的关于左卡尼汀口服溶 液的《药品注册证书》，现将有关事项公告如下： 一、药品注册证书主要信息 药品通用名称：左卡尼汀口服溶液 英文名/拉丁名：Levocarnitine Oral Solution 主要成份：左卡尼汀 注册分类：化学药品 4 类 规 格：10ml:1g 药品注册标准编号：YBH23652025 药品有效期：18 个月 申请事项：药品注册（境内生产） 包装规格： 6 支/盒 处方药/非处方药：处方药 剂 型：口服溶液剂 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、 标签及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求 方可生产销售 ...

Core Viewpoint - The approval of the drug registration certificate for L-carnitine oral solution marks a significant milestone for the company, enhancing its product pipeline and competitiveness in the chronic disease medication sector [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has received the drug registration certificate from the National Medical Products Administration for L-carnitine oral solution [1] - The L-carnitine oral solution is indicated for the treatment of primary systemic carnitine deficiency [1] - The expected sales scale for this product in public hospitals in urban and county-level areas in China is approximately 1.257 billion RMB in 2024 [1] Group 2: Market Impact - The registration certificate enables the company to sell this specific drug in the domestic market, which is anticipated to positively impact sales [1] - The introduction of this product will further enrich the company's product categories, strengthening its position in the chronic disease medication market [1]

Company Overview - Yipinhong Pharmaceutical Group Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on February 4, 2002. The company was listed on November 16, 2017. Its main business involves the research, production, and sales of proprietary drugs, as well as the sales of agency drugs [1][2]. Financial Performance - As of August 31, Yipinhong reported a revenue of 584 million yuan for the first half of 2025, a year-on-year decrease of 36.02%. The net profit attributable to shareholders was -73.54 million yuan, a year-on-year decrease of 258.30% [2]. - The company has cumulatively distributed 335 million yuan in dividends since its A-share listing, with 151 million yuan distributed over the past three years [3]. Stock Performance - On September 25, Yipinhong's stock price decreased by 2.00%, trading at 58.30 yuan per share, with a total market capitalization of 26.334 billion yuan. The stock has increased by 241.74% year-to-date but has seen a decline of 4.06% in the last five trading days and 11.84% in the last 20 days [1]. - The stock has appeared on the "龙虎榜" (a stock trading list) five times this year, with the most recent appearance on July 21, where it recorded a net purchase of 65.576 million yuan [1]. Shareholder Information - As of August 31, the number of shareholders for Yipinhong was 21,400, an increase of 0.49% from the previous period. The average circulating shares per person decreased by 0.49% to 19,553 shares [2]. - As of June 30, 2025, the eighth largest circulating shareholder is E Fund Medical Healthcare Industry Mixed A, holding 4.3661 million shares as a new shareholder, while Hong Kong Central Clearing Limited has exited the top ten circulating shareholders [3]. Industry Classification - Yipinhong belongs to the pharmaceutical and biological industry, specifically in the chemical pharmaceutical sector, with concepts including anti-influenza, pharmaceutical e-commerce, hepatitis treatment, monkeypox concept, and traditional Chinese medicine [2].

Core Viewpoint - Yipinhong's stock price has shown significant volatility, with a year-to-date increase of 252.81%, but recent declines in the short term raise questions about future performance [1][2]. Company Overview - Yipinhong Pharmaceutical Group Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on February 4, 2002, with its listing date on November 16, 2017 [1]. - The company's main business involves the research, production, and sales of its own pharmaceuticals, as well as the sales of agent pharmaceuticals [1]. - The revenue composition is as follows: Children's medicine 61.12%, Chronic disease medicine 22.71%, Others 16.17% [1]. Financial Performance - For the first half of 2025, Yipinhong reported operating revenue of 584 million yuan, a year-on-year decrease of 36.02%, and a net profit attributable to shareholders of -73.54 million yuan, a year-on-year decrease of 258.30% [2]. - The company has distributed a total of 335 million yuan in dividends since its A-share listing, with 151 million yuan distributed in the last three years [3]. Shareholder Information - As of August 31, the number of Yipinhong's shareholders was 21,400, an increase of 0.49% from the previous period, with an average of 19,553 circulating shares per person, a decrease of 0.49% [2]. - As of June 30, 2025, Yipinhong's top ten circulating shareholders included E Fund Medical Healthcare Industry Mixed A as the eighth largest shareholder, holding 4.3661 million shares, while Hong Kong Central Clearing Limited exited the top ten list [3]. Market Activity - On September 24, Yipinhong's stock price rose by 2.02% to 60.19 yuan per share, with a trading volume of 218 million yuan and a turnover rate of 0.88%, resulting in a total market capitalization of 27.187 billion yuan [1]. - The stock has appeared on the "Dragon and Tiger List" five times this year, with the most recent appearance on July 21, where it recorded a net purchase of 65.5761 million yuan [1].

"2019年以来我国制定发布多个儿童用药相关指导原则，相关部门从保障需求、鼓励研发、优先审评、 简化采购程序、扩大医保支付范围等多个方面频繁出台了儿童用药相关政策，儿童药行业正在不断迎来 顶层设计与政策支撑。公司深耕儿童药领域，将持续依托自身在儿童药产品、技术等方面的储备，把握 政策机遇，进一步提高公众对儿童用药的重视度，打造具有核心竞争力的儿童药产品。"一品红 （300723）财务总监张辉星在2025年半年度业绩说明会上表示。 一品红是一家聚焦于儿童药、创新慢病药领域的创新型生物医药企业，是中国化药研发综合实力百强企 业、中国创新力医药企业100强和中国化药企业百强企业，也是广州生物医药产业链的链主企业。 一品红董事长兼总经理李捍雄在业绩说明会上介绍说，公司现有27个儿童药品注册批件，涵盖呼吸、消 化、皮肤等多个疾病领域，覆盖幼儿、儿童、青少年整个年龄阶段，可用于治疗儿童流感、感冒、感染 性疾病、功能性消化不良、手足口病、湿疹、心脑血管等多种临床需求迫切的常见疾病。目前，公司在 研管线还有16个儿童药项目，随着各项研究及申报注册工作有序推进，将会逐步投向市场。 今年以来，一品红在研1类痛风创新药AR882( ...

证券日报网讯 9月22日晚间，一品红发布公告称，公司全资子公司广州一品红制药有限公司申报的馥感 啉颗粒（受理号：CXZL2500048）于近日获得国家药品监督管理局签发的药物临床试验批准通知书 （通知书编号：2025LP02464），同意本品开展用于成人气虚感冒的临床试验。 （文章来源：证券日报） ...

格隆汇9月22日丨一品红(300723.SZ)公布，全资子公司广州一品红制药有限公司（简称：一品红制药） 申报的馥感啉颗粒于近日获得国家药品监督管理局签发的药物临床试验批准通知书，同意本品开展用于 成人气虚感冒的临床试验。 ...

一品红（300723）(300723.SZ)公告，公司全资子公司广州一品红制药有限公司(简称：一品红制药)申报 的馥感啉颗粒于近日获得国家药品监督管理局签发的药物临床试验批准通知书，同意本品开展用于成人 气虚感冒的临床试验。 ...

一品红药业集团股份有限公司（以下简称：公司）全资子公司广州一品红制 药有限公司（以下简称：一品红制药）申报的馥感啉颗粒（受理号：CXZL2500048） 于近日获得国家药品监督管理局签发的药物临床试验批准通知书（通知书编号： 2025LP02464），同意本品开展用于成人气虚感冒的临床试验。现将有关情况公 告如下： 一、药品的基本情况 药品名称：馥感啉颗粒 受 理 号：CXZL2500048 剂 型：颗粒剂 证券代码：300723 证券简称：一品红 公告编号：2025-062 一品红药业集团股份有限公司 关于全资子公司馥感啉颗粒获得药物临床试验通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 申请事项：境内生产药品注册临床试验 疗成人气虚感冒。原剂型是公司独家持有，用于小儿气虚感冒。 在临床上，颗粒剂与口服液给药途径一致，吸收利用度通常一致，但颗粒剂 具有载药量大的特点，可以解决成人用药不便的问题；颗粒剂采用高甜度甜味剂 代替了口服液中的蜂蜜、蔗糖，可以满足糖尿病人群的糖摄入量控制需求，提高 患者服药依从性。 馥感啉颗粒是在馥感啉口服液的基础上改变 ...

Group 1 - The core point of the article is that Yipinhong Pharmaceutical's subsidiary has received approval for clinical trials of a new drug aimed at treating adult patients with Qi deficiency cold [1] Group 2 - Yipinhong Pharmaceutical's subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has been granted a clinical trial approval notice by the National Medical Products Administration [1] - The drug being tested is called Fuganling Granules, which is intended for use in adults suffering from Qi deficiency cold [1]